Loading organizations...
Humanigen is a biopharmaceutical company developing proprietary investigational therapeutics designed to prevent or treat an uncontrolled inflammatory response. Its lead product candidate, Lenzilumab, is an anti-human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody. This therapy addresses immune dysregulation in severe inflammatory conditions, including its study in patients with COVID-19, and in certain hematologic cancers and CAR-T cell therapy-associated toxicities. The company leverages a "Humaneered" platform to engineer its biologic drug candidates.
The company was founded in 2000 by Jeng Her and Robert Balint. Their insight centered on the potential of targeted biologic therapies to modulate the immune system effectively, thereby addressing complex diseases where uncontrolled inflammation plays a critical role. This foundational work laid the groundwork for developing novel antibody-based treatments that selectively interfere with disease pathways while minimizing broader immune suppression.
Humanigen's products aim to serve patients suffering from severe inflammatory responses and certain life-threatening cancers. These include individuals experiencing cytokine storm from viral infections, those undergoing CAR-T cell therapy with associated adverse effects, and patients with chronic myelomonocytic leukemia. The company's vision is to advance innovative treatments for these challenging conditions, improving patient outcomes by precisely targeting underlying immune pathologies.
Humanigen has raised $56.0M across 4 funding rounds.
Humanigen has raised $56.0M in total across 4 funding rounds.
Humanigen has raised $56.0M across 4 funding rounds. Most recently, it raised $12.0M Series D in December 2008.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2008 | $12M Series D | — | Soffinova Partners, Sofinnova Investments | Announced |
| Sep 1, 2008 | $20M Series D | — | Soffinova Partners, Sofinnova Investments | Announced |
| Mar 1, 2005 | $20M Series B | — | Soffinova Partners, Sofinnova Investments | Announced |
| Jun 1, 2003 | $4M Seed | — | Soffinova Partners, Sofinnova Investments | Announced |
Humanigen, Inc. (Nasdaq: HGEN) is a clinical-stage biopharmaceutical company developing proprietary Humaneered monoclonal antibodies to target immune hyper-responses like cytokine storm in rare diseases, immuno-oncology, and inflammatory conditions.[1][2][3][4] Its lead candidate, lenzilumab, neutralizes GM-CSF to treat cytokine storm in COVID-19 pneumonia, CAR-T therapy complications, chronic myelomonocytic leukemia (CMML), and acute graft-versus-host disease (GvHD) post-stem cell transplant; other candidates include ifabotuzumab (for myelodysplastic syndromes) and HGEN-005 (previously for asthma).[1][3][4][5] Humanigen serves patients with neglected rare diseases and hematologic cancers, addressing unmet needs in inflammation control through high-affinity, low-immunogenicity antibodies engineered from murine sources.[1][2] With only 6 employees and modest revenues ($2.51M in 2022 from U.S. pharmaceutical development), it shows focused growth via Phase 3 trials and partnerships like the UK's IMPACT network.[2][1]
Humanigen emerged from its Humaneered technology platform, a patented method to engineer high-affinity human antibodies from existing murine ones, initially targeting chronic conditions via academic in-licensing.[1][2] The company advanced through key milestones: completing a Phase 3 LIVE-AIR trial for lenzilumab in COVID-19 pneumonia (positive topline data March 2021, leading to an EUA filing), Phase 1b data reducing CAR-T side effects in DLBCL, and planning Phase 2/3 for GvHD.[1][4] Recent evolution includes shifting focus to rare diseases like Chagas (benznidazole), CMML/JMML, and PREACH-M trial updates presented at AACR 2025, building on immunology and immuno-oncology roots.[3][4] Now headquartered in Brisbane, CA (previously Short Hills, NJ), it humanizes antibody development for acute/chronic immune therapies.[2][3]
Humanigen rides the cytokine storm trend in immuno-oncology and post-pandemic inflammation therapies, where GM-CSF inhibition addresses CAR-T toxicities, GvHD, and rare hematologic diseases amid rising stem cell transplants and targeted biologics demand.[1][4][5] Timing aligns with accelerated rare disease approvals and CAR-T expansion (e.g., CD19 CAR-T collaborations), fueled by market forces like unmet needs in CMML/JMML and post-COVID immune insights.[3][4] It influences the ecosystem by pioneering antibody engineering for hyperinflammation, enabling companion therapies that improve CAR-T safety/efficacy and supporting academic-to-clinic translation.[1][2][5]
Humanigen's path forward hinges on lenzilumab advancements—PREACH-M CMML updates, GvHD trials, and potential EUA/commercialization—amid pipeline expansion in CAR-T/ADCs for solid tumors and rare indications.[4][5] Trends like AI-optimized biologics, rare disease incentives, and cytokine-targeted immuno-oncology will shape it, potentially amplifying influence via partnerships if Phase 2/3 data succeeds.[1][3] Evolving from COVID focus to niche immune therapies positions it as a cytokine storm specialist, delivering targeted impact for underserved patients.[4]
Humanigen has raised $56.0M in total across 4 funding rounds.
Humanigen's investors include Soffinova Partners, Sofinnova Investments.
